Abstract
Nanoemulsions containing hydrophobic drugs have a great potential in the pharmaceutical industries to improve thebioavailability of the drug. However, currently there is no cost-effective way of producing nanoemulsions in large scale.The need of subjecting emulsions to an extreme pressure of 50 MPa demands a large excess of energy for themanufacturing process, while low-energy method requires large amount of solvents. Here, nanoemulsions containing awell-characterized hydrophobic drug, carboxyamidotriazole (CAI), are produced in both batch and continuous modes todemonstrate the scalability of nanoemulsion production using Covaris’ Adaptive Focused Acoustics™ (AFA) technology.To move from batch scale to continuous flow, the acoustic and thermal energy inputs can be manipulated to adjust particlesize, while the composition and temperature of starting materials can be altered to achieve complete dissolution ofhydrophobic drugs, thus providing 100% encapsulation efficiency. Furthermore, using two AFA systems in series candrastically enhance the production flow rates, making AFA a competitive means for producing nanoemulsions in thepharmaceutical industry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
